Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT ID: NCT03347084
Last Updated: 2024-09-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
2 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-11-10
Study Completion Date
2023-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the proposed study is to determine the feasibility of brief brain stimulation, using a device called Low Intensity Focused Ultrasound Pulsation (LIFUP), for persons with mild cognitive impairment (MCI) or mild (early-stage) Alzheimer's disease (AD). As a secondary aim, the investigators will explore whether this brief intervention is associated with improvements in cognitive functioning immediately and one week following the intervention.
Subjects will be randomly assigned to one of two experimental groups: either the LIFUP administration will be designed to increase the activity of neurons in a certain part of the brain or decrease the activity of neurons.
The investigators will study up to 8 subjects with MCI or mild AD. Initially, subjects will undergo a screening assessment with a study physician to determine medical and psychiatric history, establish AD diagnosis, and undergo a blood draw, if standard recent labs for dementia and EKG are unavailable. Subjects that meet criteria and agree to participate in the study will undergo a follow-up visit. In the baseline measurement visit, participants will first undergo neuropsychological testing. Participants will be randomly assigned to one of two LIFUP pulsing paradigms. Participants will then be administered four successive LIFUP treatments while the participants are in a functional magnetic resonance imaging (MRI). Sixty minutes following the administration, participants will undergo a second neuropsychological test. A final follow-up assessment will be administered at one week.
Subjects will be randomly assigned to one of two experimental groups: either the LIFUP administration will be designed to increase the activity of neurons in a certain part of the brain or decrease the activity of neurons.
The investigators will study up to 8 subjects with MCI or mild AD. Initially, subjects will undergo a screening assessment with a study physician to determine medical and psychiatric history, establish AD diagnosis, and undergo a blood draw, if standard recent labs for dementia and EKG are unavailable. Subjects that meet criteria and agree to participate in the study will undergo a follow-up visit. In the baseline measurement visit, participants will first undergo neuropsychological testing. Participants will be randomly assigned to one of two LIFUP pulsing paradigms. Participants will then be administered four successive LIFUP treatments while the participants are in a functional magnetic resonance imaging (MRI). Sixty minutes following the administration, participants will undergo a second neuropsychological test. A final follow-up assessment will be administered at one week.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT05417555
Mild Cognitive Impairment
Amnestic Mild Cognitive Disorder
Deep Brain Stimulation
+1 more
RECRUITING
NA
Cognition and Ultrasound
NCT07220655
Healthy Participants
RECRUITING
NA
Effect of Modulating Gamma Oscillations Using tACS
NCT03412604
Alzheimer Disease
COMPLETED
NA
Deep Brain Stimulation of the Pedunculopontine Nucleus for Alzheimer's Disease
NCT06936124
Alzheimer Disease
RECRUITING
NA
Cognitive Outcomes of Brain Stimulation As a Later-in-Life Treatment
NCT05564715
Mild Cognitive Impairment
Dementia
Amnestic Mild Cognitive Impairment - aMCI
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Alzheimer disease (AD) is a neurodegenerative condition and the most common cause of dementia or a functional impairment in memory and other cognitive abilities. Prior to developing the functional impairment of dementia, patients develop mild cognitive impairment (MCI), which increases the risk for developing the functional impairment of dementia. Deep brain stimulation (DBS) is of interest as a potential therapeutic option for MCI and AD because it can directly target and modulate the activity of brain structures implicated in memory functioning.
Recently there have been multiple reports that DBS of different locations within the brain may be effective in improving symptoms characteristic of dementia (e.g., Heschman et al., 2013). For example, Laxton et al. (2010) performed DBS in the fornix/hypothalamus of six persons with AD in a phase I clinical trial. The investigators hypothesized that stimulation of the fornix would alter the activity of the medial temporal memory circuits, and thus delay and/or reverse memory loss. After 6-12 months, the investigators noted improvement or slowing in the progression of AD in some of the research participants, as measured by two commonly-used assessments of global cognitive function. In a recent literature review, Laxton et al. (2013) also described several additional studies demonstrating that DBS of the fornix or nucleus of Meynert or subthalamic nucleus influences the pathologic neurological circuits involved in AD.
Four separate groups recently have published reports concluding that ultrasound improves amyloid-β clearance in mouse models and restores memory (e.g., Leinenga \& Götz, 2015). This finding raises the question of whether one method of DBS, Low Intensity Focused Ultrasound Pulse (LIFUP), could improve cognition in patients with AD, which is characterized by abnormal deposition of amyloid plaques in brain regions controlling memory and thinking. The use of LIFUP in animal models is well described (Bystritsky et al., 2014). LIFUP is able to penetrate the human skull and reach deep structures within the temporal therapeutic window. The structures that are reachable by LIFUP include the temporal cortices, hippocampus, thalamus, and subthalamic nuclei, all of which are implicated in the pathophysiology of AD. The Food and Drug Administration (FDA) recently approved an investigational device exemption (IDE) to begin a feasibility and safety trial of LIFUP for persons with refractory seizures.
Although symptomatic treatments are available for AD, their modest effects are temporary and there is a need for more effective interventions. In the current project, the investigators propose to use the FDA-approved protocol to:
1. Determine the feasibility of a brief LIFUP intervention (four stimulations of 30 seconds each, with 2-minute intervals between each treatment) for persons with MCI or mild (early-stage) AD.
2. As a secondary aim, the investigators will explore whether this brief LIFUP intervention is associated with improvements on neuropsychological measures of cognitive functioning immediately following the intervention.
To investigate these aims, subjects with MCI or mild AD will be enrolled. Subjects will be randomized using a single-blind design, to one of two LIFUP pulsing paradigms in which activity of neurons in a certain part of the brain are either increased. Subjects will then be administered four successive LIFUP treatments while the subjects are in a functional magnetic resonance imaging (MRI). Neuropsychological assessments will be performed at baseline, immediately after LIFUP is administered, and one week following the conclusion of the visit.
Recently there have been multiple reports that DBS of different locations within the brain may be effective in improving symptoms characteristic of dementia (e.g., Heschman et al., 2013). For example, Laxton et al. (2010) performed DBS in the fornix/hypothalamus of six persons with AD in a phase I clinical trial. The investigators hypothesized that stimulation of the fornix would alter the activity of the medial temporal memory circuits, and thus delay and/or reverse memory loss. After 6-12 months, the investigators noted improvement or slowing in the progression of AD in some of the research participants, as measured by two commonly-used assessments of global cognitive function. In a recent literature review, Laxton et al. (2013) also described several additional studies demonstrating that DBS of the fornix or nucleus of Meynert or subthalamic nucleus influences the pathologic neurological circuits involved in AD.
Four separate groups recently have published reports concluding that ultrasound improves amyloid-β clearance in mouse models and restores memory (e.g., Leinenga \& Götz, 2015). This finding raises the question of whether one method of DBS, Low Intensity Focused Ultrasound Pulse (LIFUP), could improve cognition in patients with AD, which is characterized by abnormal deposition of amyloid plaques in brain regions controlling memory and thinking. The use of LIFUP in animal models is well described (Bystritsky et al., 2014). LIFUP is able to penetrate the human skull and reach deep structures within the temporal therapeutic window. The structures that are reachable by LIFUP include the temporal cortices, hippocampus, thalamus, and subthalamic nuclei, all of which are implicated in the pathophysiology of AD. The Food and Drug Administration (FDA) recently approved an investigational device exemption (IDE) to begin a feasibility and safety trial of LIFUP for persons with refractory seizures.
Although symptomatic treatments are available for AD, their modest effects are temporary and there is a need for more effective interventions. In the current project, the investigators propose to use the FDA-approved protocol to:
1. Determine the feasibility of a brief LIFUP intervention (four stimulations of 30 seconds each, with 2-minute intervals between each treatment) for persons with MCI or mild (early-stage) AD.
2. As a secondary aim, the investigators will explore whether this brief LIFUP intervention is associated with improvements on neuropsychological measures of cognitive functioning immediately following the intervention.
To investigate these aims, subjects with MCI or mild AD will be enrolled. Subjects will be randomized using a single-blind design, to one of two LIFUP pulsing paradigms in which activity of neurons in a certain part of the brain are either increased. Subjects will then be administered four successive LIFUP treatments while the subjects are in a functional magnetic resonance imaging (MRI). Neuropsychological assessments will be performed at baseline, immediately after LIFUP is administered, and one week following the conclusion of the visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Brain Imaging
Mild Cognitive Impairment
Alzheimer Disease
Deep Brain Stimulation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Participants will be randomly assigned to one of two LIFUP pulsing paradigms: one that excites the activity of hippocampal neurons ("Paradigm A"), or a second that inhibits them ("Paradigm B"). The participants will then be administered four successive LIFUP treatments while the participants are in a functional magnetic resonance imaging (MRI).
Primary Study Purpose
DEVICE_FEASIBILITY
Blinding Strategy
SINGLE
Participants
Participants and the participants' caregivers will be blinded to arm assignment.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Excitation
Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
Group Type
ACTIVE_COMPARATOR
Excitation
Intervention Type
DEVICE
Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Inhibition
Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
Group Type
ACTIVE_COMPARATOR
Inhibition
Intervention Type
DEVICE
Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Excitation
Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Intervention Type
DEVICE
Inhibition
Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Low Intensity Focused Ultrasound Pulse
Low Intensity Focused Ultrasound Pulse
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild cognitive impairment or mild (early-stage) AD diagnosis through medical record review
* Agreement to participate in a clinical and brain imaging study.
* Age 55 years or older.
* No significant cerebrovascular disease as determined by a modified Ischemic Score of ≤ 4.
* Availability of a study partner (next of kin, family member) to attend all visits and to provide surrogate consent should it be determined that the participant does not have capacity.
* Adequate visual and auditory acuity to allow neuropsychological testing.
* Screening laboratory tests and ECG without significant abnormalities that might interfere with the study.
* Use of cholinesterase inhibitors for AD (Aricept, Namenda, etc.) will be allowed as long as the participant has been on a stable dose for at least two months.
* There must be a family member or caregiver available to make sure the participant gives informed consent, and in case the participant develops cognitive impairment that interferes with independent study participation.
* Agreement to participate in a clinical and brain imaging study.
* Age 55 years or older.
* No significant cerebrovascular disease as determined by a modified Ischemic Score of ≤ 4.
* Availability of a study partner (next of kin, family member) to attend all visits and to provide surrogate consent should it be determined that the participant does not have capacity.
* Adequate visual and auditory acuity to allow neuropsychological testing.
* Screening laboratory tests and ECG without significant abnormalities that might interfere with the study.
* Use of cholinesterase inhibitors for AD (Aricept, Namenda, etc.) will be allowed as long as the participant has been on a stable dose for at least two months.
* There must be a family member or caregiver available to make sure the participant gives informed consent, and in case the participant develops cognitive impairment that interferes with independent study participation.
Exclusion Criteria
* Evidence of any other major neurologic or other physical illness that could produce cognitive deterioration, except for mild cognitive impairment (MCI) and any history of stroke or diabetes.
* History of myocardial infarction within the previous year or unstable cardiac disease.
* Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100), history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer.
* Major psychiatric disorders, such as bipolar disorder or schizophrenia, or persons with current untreated major depression
* Current diagnosis or significant history of alcoholism or drug dependence.
* Participants taking medications known to influence cognitive functioning will be excluded. Medications that will be excluded include: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, benzodiazepines, systemic corticosteroids, and medications with significant anticholinergic effects, anti-convulsants, or warfarin. During the screening visit, physicians will review all medications and determine whether the type, dose, and interaction of medications are likely to impact cognition and determine exclusion based on these factors.
* Use of any investigational drugs within the previous month or longer, depending on the drug's half-life.
* Contraindication for fMRI scan (e.g. metal in body, claustrophobia).
* History of myocardial infarction within the previous year or unstable cardiac disease.
* Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100), history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer.
* Major psychiatric disorders, such as bipolar disorder or schizophrenia, or persons with current untreated major depression
* Current diagnosis or significant history of alcoholism or drug dependence.
* Participants taking medications known to influence cognitive functioning will be excluded. Medications that will be excluded include: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, benzodiazepines, systemic corticosteroids, and medications with significant anticholinergic effects, anti-convulsants, or warfarin. During the screening visit, physicians will review all medications and determine whether the type, dose, and interaction of medications are likely to impact cognition and determine exclusion based on these factors.
* Use of any investigational drugs within the previous month or longer, depending on the drug's half-life.
* Contraindication for fMRI scan (e.g. metal in body, claustrophobia).
Minimum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Taylor Kuhn
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Taylor P Kuhn, PhD
Role: PRINCIPAL_INVESTIGATOR
UCLA Longevity Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Semel Institute
Los Angeles, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
World Health Organization (WHO). Dementia cases set to triple by 2050 but still largely ignored. Geneva, Switzerland; 2012.
Reference Type
BACKGROUND
Prince M, Bryce R, Ferri C. World Alzheimer report. Alzheimer's Disease International; 2011 Sep.
Reference Type
BACKGROUND
Okun MS. Deep-brain stimulation for Parkinson's disease. N Engl J Med. 2013 Jan 31;368(5):483-4. doi: 10.1056/NEJMc1214078. No abstract available.
Reference Type
BACKGROUND
Halpern C, Hurtig H, Jaggi J, Grossman M, Won M, Baltuch G. Deep brain stimulation in neurologic disorders. Parkinsonism Relat Disord. 2007 Feb;13(1):1-16. doi: 10.1016/j.parkreldis.2006.03.001. Epub 2006 Dec 1.
Reference Type
BACKGROUND
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH. Deep brain stimulation for treatment-resistant depression. Neuron. 2005 Mar 3;45(5):651-60. doi: 10.1016/j.neuron.2005.02.014.
Reference Type
BACKGROUND
Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov;31(11):2384-93. doi: 10.1038/sj.npp.1301165. Epub 2006 Jul 19.
Reference Type
BACKGROUND
Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, Kampman KM, Baltuch GH, Caplan AL, Stein SC. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction. 2012 Mar;107(3):624-34. doi: 10.1111/j.1360-0443.2011.03656.x.
Reference Type
BACKGROUND
Pisapia JM, Halpern CH, Williams NN, Wadden TA, Baltuch GH, Stein SC. Deep brain stimulation compared with bariatric surgery for the treatment of morbid obesity: a decision analysis study. Neurosurg Focus. 2010 Aug;29(2):E15. doi: 10.3171/2010.5.FOCUS10109.
Reference Type
BACKGROUND
Hescham S, Lim LW, Jahanshahi A, Blokland A, Temel Y. Deep brain stimulation in dementia-related disorders. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2666-75. doi: 10.1016/j.neubiorev.2013.09.002. Epub 2013 Sep 20.
Reference Type
BACKGROUND
Hardenacke K, Kuhn J, Lenartz D, Maarouf M, Mai JK, Bartsch C, Freund HJ, Sturm V. Stimulate or degenerate: deep brain stimulation of the nucleus basalis Meynert in Alzheimer dementia. World Neurosurg. 2013 Sep-Oct;80(3-4):S27.e35-43. doi: 10.1016/j.wneu.2012.12.005. Epub 2012 Dec 12.
Reference Type
BACKGROUND
Fontaine D, Deudon A, Lemaire JJ, Razzouk M, Viau P, Darcourt J, Robert P. Symptomatic treatment of memory decline in Alzheimer's disease by deep brain stimulation: a feasibility study. J Alzheimers Dis. 2013;34(1):315-23. doi: 10.3233/JAD-121579.
Reference Type
BACKGROUND
Sankar T, Tierney TS, Hamani C. Novel applications of deep brain stimulation. Surg Neurol Int. 2012;3(Suppl 1):S26-33. doi: 10.4103/2152-7806.91607. Epub 2012 Jan 14.
Reference Type
BACKGROUND
Laxton AW, Lozano AM. Deep brain stimulation for the treatment of Alzheimer disease and dementias. World Neurosurg. 2013 Sep-Oct;80(3-4):S28.e1-8. doi: 10.1016/j.wneu.2012.06.028. Epub 2012 Jun 19.
Reference Type
BACKGROUND
Vitek JL. Long-term benefit from deep brain stimulation of the subthalamic nucleus: is it for everyone? Alzheimers Res Ther. 2012 May 9;4(3):13. doi: 10.1186/alzrt111.
Reference Type
BACKGROUND
Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaconescu AO, Workman CI, Lozano AM. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol. 2012 Sep;69(9):1141-8. doi: 10.1001/archneurol.2012.590.
Reference Type
BACKGROUND
Lyons MK. Deep brain stimulation: current and future clinical applications. Mayo Clin Proc. 2011 Jul;86(7):662-72. doi: 10.4065/mcp.2011.0045. Epub 2011 Jun 6.
Reference Type
BACKGROUND
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, Wherrett J, Naglie G, Hamani C, Smith GS, Lozano AM. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010 Oct;68(4):521-34. doi: 10.1002/ana.22089.
Reference Type
BACKGROUND
Laxton AW, Lipsman N, Lozano AM. Deep brain stimulation for cognitive disorders. Handb Clin Neurol. 2013;116:307-11. doi: 10.1016/B978-0-444-53497-2.00025-5.
Reference Type
BACKGROUND
Leinenga G, Gotz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer's disease mouse model. Sci Transl Med. 2015 Mar 11;7(278):278ra33. doi: 10.1126/scitranslmed.aaa2512.
Reference Type
BACKGROUND
Wood H. Alzheimer disease: scanning ultrasound elicits amyloid-beta clearance in mice. Nat Rev Neurol. 2015 May;11(5):247. doi: 10.1038/nrneurol.2015.54. Epub 2015 Mar 31. No abstract available.
Reference Type
BACKGROUND
Lin WT, Chen RC, Lu WW, Liu SH, Yang FY. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. Sci Rep. 2015 Apr 15;5:9671. doi: 10.1038/srep09671.
Reference Type
BACKGROUND
Burgess A, Dubey S, Yeung S, Hough O, Eterman N, Aubert I, Hynynen K. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology. 2014 Dec;273(3):736-45. doi: 10.1148/radiol.14140245. Epub 2014 Sep 15.
Reference Type
BACKGROUND
Bystritsky A, Korb AS, Douglas PK, Cohen MS, Melega WP, Mulgaonkar AP, DeSalles A, Min BK, Yoo SS. A review of low-intensity focused ultrasound pulsation. Brain Stimul. 2011 Jul;4(3):125-36. doi: 10.1016/j.brs.2011.03.007. Epub 2011 Apr 1.
Reference Type
BACKGROUND
Rosen WG. Verbal fluency in aging and dementia. J Clin Neuropsychol. 1980;2(2):135-46. doi: 10.1080/01688638008403788.
Reference Type
BACKGROUND
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Washington, DC: American Psychiatric Association; 2013.
Reference Type
BACKGROUND
Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997 Oct 22-29;278(16):1363-71.
Reference Type
BACKGROUND
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. doi: 10.1212/wnl.44.12.2308.
Reference Type
BACKGROUND
Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982 May;37(3):323-9. doi: 10.1093/geronj/37.3.323.
Reference Type
BACKGROUND
Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271-84. doi: 10.1016/0006-3223(88)90038-8.
Reference Type
BACKGROUND
Bushberg JT, Seibert JA, Leidholdt EM Jr., Boone JM. The essential physics of medical imaging (3rd ed). Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
Reference Type
BACKGROUND
American Institute of Ultrasound in Medicine. Official statement on "Safety in training and research." http://www.aium.org/officialStatements/36. Published 2012 Apr 1; Accessed 2015 Sep 22.
Reference Type
BACKGROUND
Yoo SS, Bystritsky A, Lee JH, Zhang Y, Fischer K, Min BK, McDannold NJ, Pascual-Leone A, Jolesz FA. Focused ultrasound modulates region-specific brain activity. Neuroimage. 2011 Jun 1;56(3):1267-75. doi: 10.1016/j.neuroimage.2011.02.058. Epub 2011 Feb 24.
Reference Type
BACKGROUND
Korb AS, Shellock FG, Cohen MS, Bystritsky A. Low-intensity focused ultrasound pulsation device used during magnetic resonance imaging: evaluation of magnetic resonance imaging-related heating at 3 Tesla/128 MHz. Neuromodulation. 2014 Apr;17(3):236-41; discussion 241. doi: 10.1111/ner.12075. Epub 2013 May 10.
Reference Type
BACKGROUND
Zeineh MM, Engel SA, Thompson PM, Bookheimer SY. Unfolding the human hippocampus with high resolution structural and functional MRI. Anat Rec. 2001 Apr;265(2):111-20. doi: 10.1002/ar.1061.
Reference Type
BACKGROUND
Ekstrom A. How and when the fMRI BOLD signal relates to underlying neural activity: the danger in dissociation. Brain Res Rev. 2010 Mar;62(2):233-44. doi: 10.1016/j.brainresrev.2009.12.004. Epub 2009 Dec 21.
Reference Type
BACKGROUND
Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42. doi: 10.1073/pnas.0308627101. Epub 2004 Mar 15.
Reference Type
BACKGROUND
Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009 Jan;19(1):72-8. doi: 10.1093/cercor/bhn059. Epub 2008 Apr 9.
Reference Type
BACKGROUND
Murphy K, Birn RM, Handwerker DA, Jones TB, Bandettini PA. The impact of global signal regression on resting state correlations: are anti-correlated networks introduced? Neuroimage. 2009 Feb 1;44(3):893-905. doi: 10.1016/j.neuroimage.2008.09.036. Epub 2008 Oct 11.
Reference Type
BACKGROUND
Brandt J, Benedict R. Hopkins Verbal Learning Test-Revised: Professional Manual. PAR: Florida; 2001.
Reference Type
BACKGROUND
46Benedict RHB. Brief Visuospatial Memory Test - Revised: Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc; 1997
Reference Type
BACKGROUND
Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E. Development and validation of the Geriatric Anxiety Inventory. Int Psychogeriatr. 2007 Feb;19(1):103-14. doi: 10.1017/S1041610206003504.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
Analysis Group, Oxford, UK. FMRIB Software Library v5.0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-001314
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease
NCT01847586
COMPLETED
NA
Executive Function Training Intervention for Chronic Traumatic Brain Injury
NCT03704116
COMPLETED
NA
Transcranial Pulse Stimulation of the Brain
NCT05910619
RECRUITING
NA
tFUS for Memory in mNCD and Healthy Adults
NCT06718140
ENROLLING_BY_INVITATION
PHASE1
Clinical Exploratory Research of Medial Prefrontal Cortex Combined With Dorsolateral Prefrontal Cortex Electrical Stimulation in the Treatment of Alzheimer's Disease
NCT05971030
UNKNOWN
NA
Neuromodulation of Cognition in Older Adults
NCT02137122
COMPLETED
NA
Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury
NCT04504630
COMPLETED
NA
Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation
NCT06094192
RECRUITING
NA
Efficacy of Multidimensional Management of Mild Traumatic Brain Injury
NCT03811626
COMPLETED
NA
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
NCT05326750
RECRUITING
NA
Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia
NCT03750409
UNKNOWN
NA
Rehabilitation of Working Memory and Brain Plasticity After Traumatic Brain Injury: Plastim-MDTC
NCT03513133
UNKNOWN
NA
Cognitive Ability Training for Seniors With Mild Cognitive Impairment
NCT02940457
WITHDRAWN
NA
Brain Training to Enhance Frontal Lobe Reasoning
NCT01552473
COMPLETED
NA
Network Modulation in Alzheimer's Disease
NCT04045990
COMPLETED
NA
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
NCT04558164
RECRUITING
NA
Ultrasonic Neuromodulation for Treatment of Cognitive Impairment
NCT06135051
TERMINATED
PHASE1/PHASE2
Improvement of Memory in Mild Cognitive Impairment
NCT05708001
RECRUITING
NA
Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation
NCT04647032
COMPLETED
NA
Combining tDCS and Neurorehabilitation to Treat Age-related Deficits of Mobility and Cognition: UPfront Walking Study
NCT03122236
COMPLETED
NA
Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans with a History of TBI
NCT04560946
COMPLETED
NA
Personalized Brain Stimulation for Cognitive Impairment in Older Adults
NCT07208734
ENROLLING_BY_INVITATION
NA
Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury
NCT06848140
RECRUITING
NA
Transcranial Magnetic Stimulation in Disorder of Consciousness in Acute Severe Cerebrovascular Disease Patients
NCT05670873
NOT_YET_RECRUITING
NA
Treating Mild Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation
NCT04869059
RECRUITING
NA